Hunan Nucien Pharmaceutical Co., Ltd. (SHA:688189)
China flag China · Delayed Price · Currency is CNY
6.25
-0.28 (-4.29%)
At close: Jul 30, 2026

SHA:688189 Financials Overview

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
127.35141.93251.72720.06698.83743.66
Revenue Growth
-18.35%-43.62%-65.04%3.04%-6.03%-27.74%
Gross Profit
22.6637.21122.12598.53580.98636.89
Operating Income
-109.62-101.02-347.984.33-79.6-216.16
Net Income
-142.12-136.9-346.51-10.87-78.83-161.88
Earnings Per Share
-0.52-0.50-1.26-0.04-0.29-0.59
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
278.09301.52490.27665.76713.47730.67
Total Debt
1010.03219.12324.6543.65475.38
Net Cash (Debt)
268.09291.49271.15341.16169.82255.29
Net Cash Growth
-18.90%7.50%-20.52%100.89%-33.48%-58.59%
Net Cash Per Share
0.981.060.991.240.620.93

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
3.36114.571.39215.23-160.09-63.11
Capital Expenditures
-49.22-79.8-58.43-31.49-41.01-113.59
Free Cash Flow
-45.8634.77-57.03183.74-201.1-176.7
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
17.79%26.22%48.51%83.12%83.14%85.64%
Operating Margin
-86.08%-71.18%-138.24%0.60%-11.39%-29.07%
Pretax Margin
-109.76%-93.53%-149.64%-1.27%-10.59%-28.88%
Profit Margin
-111.59%-96.46%-137.65%-1.51%-11.28%-21.77%
FCF Margin
-36.01%24.50%-22.66%25.52%-28.78%-23.76%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-15.1615.1615.1615.1615.16
P/FCF Ratio
-62.48-14.08--
PS Ratio
13.3515.317.093.594.846.63